Raymond James downgraded GoodRx (GDRX) to Outperform from Strong Buy with a price target of $5, down from $9. The company’s Q2 results were inline with expectations but its guidance was cut on Rite Aid store closures and pharmacy benefit managers actions around integrated savings programs, the analyst tells investors in a research note. The firm believes investors are frustrated with GoodRx’s multiple guidance cuts since the May 2024 analyst day.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX: